Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_assertion type Assertion NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_head.
- NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_assertion description "[In the attempt to find alternative therapeutic regimes for such patients, we tested PHA-848125, an oral pan cyclin-dependent kinase inhibitor currently under evaluation in phase II clinical trial, on a transgenic mouse model, K-Ras(G12D)LA2, which develops pulmonary cancerous lesions reminiscent of human lung adenocarcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_provenance.
- NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_assertion evidence source_evidence_literature NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_provenance.
- NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_assertion SIO_000772 20197397 NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_provenance.
- NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_assertion wasDerivedFrom befree-2016 NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_provenance.
- NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_assertion wasGeneratedBy ECO_0000203 NP797224.RARjnocn9VmipDvYRGb8-sL0KmWrQ2BB5uq9oecAwrTbM130_provenance.